FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

The FDA issued a warning letter to ProRx, a compounding facility in Exton, Penn., after an inspection raised serious concerns regarding the safety and compliance of its drug products. The facility, ...

Ricks said, displaying a chart that showed ... compounded tirzepatide by mid-March. Investors seemed only somewhat convinced by Ricks’s reassurances. The stock was up 1.2% early Wednesday ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists often partially inform or misinform consumers.

LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal first quarter 2025 results along with program updates, progress in its GLP-1 trials, a capital ...

GLP-1-directed drugs have already shown promise in clinical trials involving people with sleep apnoea – Lilly's Zepbound (tirzepatide) was approved for that indication in the US last year ...

Liraglutide was the medication evaluated in six trials, with exenatide, semaglutide and tirzepatide assessed in one trial each. Participants receiving a GLP-1 drug had a mean 8.1 kg body weight ...

Novo sells semaglutide as Ozempic, Rybelsus and Wegovy. The CMS will treat the different forms as a single product in price ...

Lexaria intends to add a 5th study arm - using DehydraTECH-tirzepatide in an oral capsule - to its 12-week human study already underway in Australia (study GLP-1-H24-4). In that study arm ...

and colleagues examined advertising practices of websites selling compounded GLP-1 RAs, including semaglutide, tirzepatide, and liraglutide. The researchers found that 98 unique websites sold any ...